Navigation Links
Oppenheimer's Investment Bank Continues Expansion -- Lance Alstodt Named Managing Director - Healthcare
Date:10/7/2009

NEW YORK, Oct. 7 /PRNewswire/ -- Oppenheimer & Co. Inc., a unit of Oppenheimer Holdings, is pleased to announce that Lance Alstodt will join the firm as Managing Director in Healthcare in the firm's burgeoning Investment Banking area. He will report to Brian McCarthy, Oppenheimer's Head of Healthcare Investment & Corporate Banking.

"Lance is an experienced and very capable senior banker in the medical technology space. He will be a real driver of our medical technology effort and is an important addition to the firm," said Brian McCarthy.

Lance joins Oppenheimer from Bank of America Merrill Lynch, where he worked in both the Global Mergers & Acquisitions and Global Healthcare Investment Banking Groups, generating and executing financing and advisory transactions in the Medical Technology sector.

Before moving to Bank of America Merrill Lynch, Lance had worked in the Global Mergers and Acquisitions Group at JP Morgan Chase, with a focus on Healthcare.

"Medical technology is an important piece of our Healthcare investment banking practice and we view Lance as a highly strategic hire and we're delighted he has joined us," said Marshall Heinberg, Oppenheimer's Head of Investment & Corporate Banking.

Oppenheimer & Co. Inc. (Oppenheimer), a principal subsidiary of Oppenheimer Holdings Inc. (OPY on the New York Stock Exchange), provides a full range of wealth management, securities brokerage and investment banking services to high-net-worth individuals, families, corporate executives, local governments, businesses and institutions.

Certain statements in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially, as discussed in the Company's filings with the Securities and Exchange Commission.

SOURCE Oppenheimer & Co. Inc.


'/>"/>
SOURCE Oppenheimer & Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sequella Receives American Recovery and Reinvestment Funding Through the NIH
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
4. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Health Robotics CytoCare(TM) Global Expansion Continues With Grifols International in Latin America
7. Cord Blood America Continues to Reduce Debt; Three Notes Retired
8. Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction
9. TMS Health Continues to Expand - Adding Over 60 New Jobs at Boca Raton Headquarters
10. Abbotts XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
11. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... pharmaceutical company focused on the development of oral drug ... its meeting with the U.S. Food and Drug Administration ... At the meeting, ... for submission of ORMD-0801, would be a Biologics License ...
(Date:8/31/2017)... PM360,s annual Innovations Issue, published in ... innovations happening across the industry. Established six years ago, ... providing a comprehensive look at the newest and most ... innovative companies, startups, divisions, products, services, and strategies from ... "Everyone in this industry wants to do better—in all ...
(Date:8/28/2017)... Aesculight ®, a division of LightScalpel ®, LLC, is announcing its ... 20 years of American veterinary laser surgery innovation, Aesculight® is revolutionizing veterinary ... ... with his new VetScalpel laser. Dr. Duclos practices veterinary dermatology at the ... ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... Compliancy Group is ... software, The Guard®, has helped another long-time client pass their Department of Health ... satisfy the law. , Thanks to the help of the Compliancy Group's Audit ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Centers for Medicare ... Rule that it will transition to using only Worksheet S-10 to distribute Disproportionate Share ... of three live 60-minute complimentary webinars on October 17, 2017 at 2 ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... ... for overcoming addiction. “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the ... extensive background in the field of addiction and homeless services, including more than ...
(Date:9/20/2017)... ... ... “The Foggy Road to Moorwick”: the adventures of a young Scottish girl yearning to see ... Liston, a busy mother of five who used her time waiting for children to finish ... over twenty years. It was a way to give some meaning to the hours ...
(Date:9/19/2017)... ... September 19, 2017 , ... Only a few physicians ... include Brevard’s own Ross A. Clevens, MD, FACS . The founder and medical ... Plastic and Reconstructive Surgeon who trained at Yale, Harvard and the University of Michigan. ...
Breaking Medicine News(10 mins):